Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Kaposiform hemangioendothelioma
Kasabach-Merritt phenomenon
coagulopathy
embolization
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
revised:
16
10
2020
received:
15
09
2020
accepted:
09
11
2020
pubmed:
25
11
2020
medline:
8
9
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor in children, which can be accompanied by life-threatening thrombocytopenia, referred to as Kasabach-Merritt phenomenon (KMP). The mTOR inhibitor sirolimus is emerging as targeted therapy in KHE. As the sirolimus effect on KHE occurs only after several weeks, we aimed to evaluate whether additional transarterial embolization is of benefit for children with KHE and KMP. Seventeen patients with KHE and KMP acquired from 11 hospitals in Germany were retrospectively divided into two cohorts. Children being treated with adjunct transarterial embolization and systemic sirolimus, and those being treated with sirolimus without additional embolization. Bleeding grade as defined by WHO was determined for all patients. Response of the primary tumor at 6 and 12 months assessed by magnetic resonance imaging (MRI), time to response of KMP defined as thrombocyte increase >150 × 10
Substances chimiques
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2345-2351Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013;162:142-147.
Wildgruber M, Sadick M, Müller-Wille R, Wohlgemuth WA. Vascular tumors in infants and adolescents. Insights Imaging. 2019;10:30.
Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon. Br J Dermatol. 2018;179:457-463.
O'Rafferty C, O'Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol. 2015;171:38-51.
Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100:1377-1386.
Drolet BA, Scott LA, Esterly NB, Gosain AK. Early surgical intervention in a patient with Kasabach-Merritt phenomenon. J Pediatr. 2001;138:756-758.
Liu XH, Li JY, Qu XH, et al. Treatment of kaposiform hemangioendothelioma and tufted angioma. Int J Cancer. 2016;139:1658-1666.
Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, Bernabeu-Wittel J, Ramirez-Villar GL. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2013;60:1478-1481.
MacFarland SP, Sullivan LM, States LJ, et al. Management of refractory pediatric Kaposiform hemangioendothelioma with sirolimus and aspirin. J Pediatr Hematol Oncol. 2018;40:e239-e242.
Drolet BA, Trenor CC 3rd, Brandão LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013;163:285-291.
Yesudian PD, Parslew R, Klafowski J, Gould D, Pizer B. Tufted angioma-associated Kasabach-Merritt syndrome treated with embolization and vincristine. Plast Reconstr Surg. 2008;121:692-693.
Freixo C, Ferreira V, Martins J, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review. J Vasc Surg. 2020;71:318-327.
Sakata N, Suenobu SI, Okano M, Ueda S, Kimura M, Takemura T. Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis. Rare Tumor. 2018;10:2036361318776185.
Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. Int J Cancer. 2017;141:848-855.
Wang H, Guo X, Duan Y, Zheng B, Gao Y. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma. Pediatr Dermatol. 2018;35:635-638.
Tan X, Zhang J, Zhou S, Liu Z, Zhang T, Xia J. Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus. J Dermatol. 2018;45:580-583.
Wang Z, Yao W, Sun H, et al. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. J Dermatol. 2019;46:956-961.
Boccara O, Puzenat E, Proust S, et al. The effects of sirolimus on Kasabach-Merritt phenomenon coagulopathy. Br J Dermatol. 2018;178:e114-e116.
Nadal M, Giraudeau B, Tavernier E, Jonville-Bera AP, Lorette G, Maruani A. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereol. 2016;96:448-452.
Schmid I, Klenk AK, Sparber-Sauer M, Koscielniak E, Maxwell R, Häberle B. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options. World J Pediatr. 2018;14:322-329.
Schroeder U, Lauten M, Stichtenoth G, Gebhard MP, Buchholz M, Kaiser MM. Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by supraglottoplasty and sirolimus. Klinische Padiatrie. 2014;226:362-368.
Josephson CD, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood. 2012;120:748-760.
Adams DM, Brandão LR, Peterman CM, et al. Vascular anomaly cases for the pediatric hematologist oncologists-an interdisciplinary review. Pediatr Blood Cancer. 2018;65:1.
Tan X, Chen M, Zhang J, et al. Treatment of corticosteroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon in infants: an approach with transcatheter arterial embolization plus vincristine therapy. J Vasc Interv Radiol. 2016;27:569-575.
Mariani LG, Schmitt IR, Garcia CD, Kiszewski AE. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2019;66:e27810.